The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis
- PMID: 29595655
- PMCID: PMC5895387
- DOI: 10.1097/MD.0000000000010197
The prognostic value of circulating cell-free DNA in breast cancer: A meta-analysis
Abstract
Background: Circulating cell-free DNA (cfDNA) isolated from plasma or serum by noninvasive procedures can serve as a "liquid biopsy" and has potential as a biomarker for the tumor burden and survival prediction of breast cancer (BC). However, its prognostic value in patients with BC is currently under debate. The aim of this meta-analysis was to investigate the relationship between cfDNA and survival outcome.
Methods: We systematically searched PubMed, Embase, and Science Citation Index electronic databases for studies about the prognostic utility of cfDNA in patients with BC. The clinical characteristics, relapse/disease-free survival (RFS/DFS), and overall survival (OS) data were extracted from the eligible studies. The hazard ratios (HR) and 95% confidence intervals (CI) were calculated and pooled with a fixed-effects model using the Stata12.0 software. Subgroup and sensitivity analyses were also performed.
Results: This meta-analysis included a total of 10 eligible studies and 1127 patients with BC. The pooled HR with 95% CI showed strong associations between cfDNA and OS (HR = 2.41, 95% CI, 1.83-3.16) along with DFS/RFS (HR = 2.73, 95% CI, 2.04-3.67) in patients with BC. Although publication bias was found in the studies regarding RFS/DFS, further trim and fill analysis revealed that the adjusted HR would be 2.53 (95% CI, 1.83-3.51), which is close to the original HR. Subgroup analyses confirmed the role of cfDNA as a strong prognostic marker in patients with BC, regardless of cfDNA analysis, sampling time, sample source, detection method, tumor stage, sample size, or area.
Conclusions: Our meta-analysis indicates that cfDNA is a strong predictive and prognostic marker in patients with BC.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Predictive value of circulating cell-free DNA in the survival of breast cancer patients: A systemic review and meta-analysis.Medicine (Baltimore). 2018 Jul;97(28):e11417. doi: 10.1097/MD.0000000000011417. Medicine (Baltimore). 2018. PMID: 29995790 Free PMC article. Review.
-
High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.Cancer Med. 2020 Aug;9(16):5922-5931. doi: 10.1002/cam4.3258. Epub 2020 Jun 29. Cancer Med. 2020. PMID: 32602248 Free PMC article.
-
The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis.J Cancer. 2016 Jun 4;7(9):1105-13. doi: 10.7150/jca.14801. eCollection 2016. J Cancer. 2016. PMID: 27326254 Free PMC article.
-
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.Gene. 2019 Sep 25;714:143993. doi: 10.1016/j.gene.2019.143993. Epub 2019 Jul 19. Gene. 2019. PMID: 31330238 Review.
-
The prognostic value of the C-reactive protein to albumin ratio in cancer: An updated meta-analysis.Medicine (Baltimore). 2020 Apr;99(14):e19165. doi: 10.1097/MD.0000000000019165. Medicine (Baltimore). 2020. PMID: 32243358 Free PMC article.
Cited by
-
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.Breast Care (Basel). 2019 Aug;14(4):224-245. doi: 10.1159/000501000. Epub 2019 Aug 6. Breast Care (Basel). 2019. PMID: 31558897 Free PMC article. Review. No abstract available.
-
Clinical relevance and prognostic role of preoperative cell-free single-stranded DNA concentrations in colorectal cancer patients.Korean J Clin Oncol. 2021 Dec;17(2):59-67. doi: 10.14216/kjco.21010. Epub 2021 Dec 31. Korean J Clin Oncol. 2021. PMID: 36945669 Free PMC article.
-
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA.Oncol Res Treat. 2022;45(1-2):4-11. doi: 10.1159/000520561. Epub 2021 Oct 29. Oncol Res Treat. 2022. PMID: 34718243 Free PMC article. Review.
-
Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm.Diagnostics (Basel). 2021 Nov 23;11(12):2171. doi: 10.3390/diagnostics11122171. Diagnostics (Basel). 2021. PMID: 34943407 Free PMC article.
-
Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.Int J Mol Sci. 2023 Dec 2;24(23):17073. doi: 10.3390/ijms242317073. Int J Mol Sci. 2023. PMID: 38069396 Free PMC article. Review.
References
-
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108. - PubMed
-
- Siegel R, Ma JM, Zou ZH, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29. - PubMed
-
- Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010;411:1869–74. - PubMed
-
- Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 2013;133:1–3. - PubMed
-
- Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l’homme. C R Seances Soc Biol Fil 1948;142:241–3. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical